CN112870290B - 一种祛斑解郁组合物及其制备方法 - Google Patents
一种祛斑解郁组合物及其制备方法 Download PDFInfo
- Publication number
- CN112870290B CN112870290B CN202110157222.4A CN202110157222A CN112870290B CN 112870290 B CN112870290 B CN 112870290B CN 202110157222 A CN202110157222 A CN 202110157222A CN 112870290 B CN112870290 B CN 112870290B
- Authority
- CN
- China
- Prior art keywords
- composition
- volatile oil
- folic acid
- resolving
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000341 volatile oil Substances 0.000 claims abstract description 45
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 34
- 241001506047 Tremella Species 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 20
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 20
- 239000005017 polysaccharide Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011724 folic acid Substances 0.000 claims abstract description 18
- 235000019152 folic acid Nutrition 0.000 claims abstract description 18
- 229960000304 folic acid Drugs 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000628997 Flos Species 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229920000858 Cyclodextrin Polymers 0.000 claims description 18
- 241000220317 Rosa Species 0.000 claims description 18
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 16
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- 150000002224 folic acids Chemical class 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 206010014970 Ephelides Diseases 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 229940065207 methylfolic acid Drugs 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 206010025421 Macule Diseases 0.000 claims 5
- -1 folic acid compound Chemical class 0.000 claims 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 2
- 238000001256 steam distillation Methods 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 206010008570 Chloasma Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 10
- 208000019901 Anxiety disease Diseases 0.000 description 9
- 230000036506 anxiety Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000011201 Ginkgo Nutrition 0.000 description 8
- 241000218628 Ginkgo Species 0.000 description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 244000248557 Ophiopogon japonicus Species 0.000 description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000005562 fading Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 206010054196 Affect lability Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229930195210 Ophiopogon Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000008207 calcium folinate Nutrition 0.000 description 2
- 239000011687 calcium folinate Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241001448421 Ophiopogon jaburan Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 235000020803 food preference Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及祛斑产品领域,具体涉及一种适合产妇用的祛斑解郁组合物及其应用,其原料含有玫瑰花、银耳多糖、麦冬与叶酸,遵循中医辨证施治的原则,配方各味药相辅相成。其制备方法包括将玫瑰花和麦冬先水蒸气蒸馏法提取挥发油,并进行包合;滤过药渣加一定浓度的丙酮‑乙醇水溶液提取,浓缩干燥得到的干膏粉和挥发油包合物及银耳多糖和叶酸混合制备成祛斑组合物,本发明组合物具有明显的祛斑、缓解焦虑、改善睡眠的效果,并且安全可靠。
Description
技术领域
本发明涉及祛斑产品领域,具体涉及一种适合产妇用的祛斑解郁组合物及其应用。
背景技术
随着社会的发展和人们生活水平的不断提高,人们对自己的外表越来越重视,色斑成了生活中长时间困扰人们的问题。色斑形成的原因:一是紫外线照射,阳光中的紫外线照射是色斑形成的重要原因之一,当皮肤过多的接触阳光中的紫外线,就会产生大量的黑色素;二是压力与生活习惯,压力大、偏食、睡眠时间不稳定,会导致面色晦暗、粗糙,加速黑色素产生;三是辐射,长时间使用电脑,肌肤会因辐射感觉不适,面部已长的色斑也会加深,和紫外线很像;四是激素分泌失调,激素失调是女性产生色斑的一个重要原因,经期和妊娠期体内激素水平的变化,可以影响黑色素的产生。情绪的不稳定也可以加速色斑的产生;五是滥用化妆品、药物等其他因素。
目前市场上的淡斑产品多种多样,但是大部分的淡斑产品的安全性与可靠性难以保证,使用不当时会造成皮肤的严重损伤,而且目前大部分产品不会对已经损伤的细胞进行修复,而是直接利用“层层剥皮”的方式进行美白,效果难以预测,且容易对皮肤造成损伤,且药味均较多,生产过程中对原料的来源控制比较难。
中医认为,肝失条达,气机郁结,郁久化火,灼伤阴血,血行不畅,可导致颜面气血失和;脾气虚弱,运化失健,不能化生精微,则气血不能润泽于颜面;肾阳不足,肾精亏虚等病理变化均可导致颜面发生黄褐斑。产妇由于体质的特殊性,产后极易出现“内虚”、免疫力差、焦虑等症状,更容易形成妊娠斑、黄褐斑等,目前市面上的大部分祛斑产品并不适合产妇使用,在制备供产妇使用的祛斑产品时,最好是不含激素和化学有害物质的天然成分。
中国发明专利申请CN108785459A公开了一种适合孕妇用的祛斑组合物及其应用,按照重量份计,该祛斑组合物含有0.5-7.5份番茄红素、10-30份葡萄籽提取物和5-50份银耳多糖,此外,按照重量份计,该祛斑组合物中还添加有0.01-0.05份叶酸、10-30份玫瑰花提取物和1-20份透明质酸钠,玫瑰花提取物和透明质酸钠的添加,使该组合物在祛斑的同时,还能帮助孕期女性改善睡眠质量。该发明药味简单,但祛斑效果有待进一步提高。
中国发明专利申请CN103191037A公开了一种银杏美白祛痘霜,包括银杏膏、茶油、抗氧化剂、香精抑菌剂,所述的银杏膏按以下方法制得:银杏果去壳去皮、清洗后,得银香果肉,加纯净水,搅拌打碎至1000目以下,得膏状物,然后紫外线杀菌,制得所述银杏膏:所述银查果肉、纯净水的质量比为7-12:1,该发明声称制得的银杏美白祛痘霜利用天然银杏核的祛痘美白效果,可减轻或消除面部青春痘。但是并未说明其具有祛斑作用,并且银杏果未经提取,具有一定的毒性,不易于孕妇用。
因此急需开发一种适合于产妇食用的可明显祛斑,缓解焦虑的祛斑组合物,其具有潜在的社会效益及经济价值。
发明内容
针对现有技术存在的不足,本发明欲解决的问题是现有技术中没有专门针对适合产妇用的、处方简单、无毒副作用的祛斑解郁产品的技术问题。本发明提供一种适合产妇用的祛斑组合物,配方各味药相辅相成,具有明显的祛斑、紧致肌肤、除皱、缓解焦虑的效果,并且安全可靠,食用方式方便快捷。
本发明的一个目的在于提供一种适合产妇用的祛斑组合物,包括如下原料:玫瑰花、银耳多糖、麦冬和叶酸类化合物。
优选地,该组合物包括如下重量份数的原料:玫瑰花20-50份、银耳多糖20-50份、麦冬10-20份和叶酸类化合物0.01-0.02份。
优选地,该组合物包括如下重量份数的原料:玫瑰花30-40份、银耳多糖30-40份、麦冬10-15份和叶酸类化合物0.01-0.02份。
优选地,该组合物包括玫瑰花35份、银耳多糖35份、麦冬15份和叶酸类化合物0.015份。
优选地,叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐、叶酸或叶酸可药用盐的活性代谢产物和可在体内代谢和/或生成叶酸的物质中的一种或几种。
本发明对以上原料来源没有特殊限制,采用本领域技术人员熟知的市售商品即可。
本发明的另一目的是提供一种上述祛斑解郁组合物的制备方法,包括如下步骤:
(1)将麦冬粉碎,与玫瑰花混合经水蒸气蒸馏提取挥发油,药渣加水提取、浓缩、干燥得干膏粉;优选地将麦冬粉碎,与玫瑰花混合加5-8倍量水蒸馏提取挥发油,提取5-7h,收集挥发油,提取液过滤,得滤液1,滤渣加4-6倍量的体积比为30:(50-60):(10-20)的水-乙醇-丙酮溶液,回流提取1-3h,过滤得滤液2,合并滤液1和滤液2,浓缩,干燥,得干膏粉;
(2)将挥发油用β-环糊精包合,得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和叶酸类化合物混合均匀,制成祛斑组合物颗粒。
优选地将干膏粉、挥发油包合物、银耳多糖和叶酸类化合物混合均匀后,得祛斑组合物。
优选地,步骤(2)中所述的包合温度为40-60℃,所述挥发油与β-环糊精的质量比为1:2.5-4。
优选地,步骤(1)中所述过筛为过24-65目筛;所述浓缩为浓缩至60℃下相对密度为1.05±0.05;所述干燥均为减压真空干燥,干燥至干膏粉中水分的含量≤8%。
优选地,步骤(3)混合后还包括在60~70℃下干燥消毒1~3小时,经粉碎,过筛,即得。
本发明的再一目的是提供一种上述祛斑组合物或上述制备方法制备的祛斑解郁组合物在制备祛斑食品、保健品或药品中的应用。
本发明的有益效果:
1、本发明的组合物针对女性产后这一特殊时期,采用中医基础理论合理组方,经研究,本发明组合物具有明显的祛斑功效,并且可明显缓解产妇的焦虑情绪。
2、本发明的组合物中叶酸,除了能与其他组分协同发挥祛斑解郁功效外,还能够提高产妇的新陈代谢,为产妇补充叶酸,改善产妇内虚、免疫力差的体质。
3、本发明的组合物中采用理气、和血散瘀的玫瑰花、银耳多糖和养阴生津的麦冬配伍,协同叶酸在改善产妇的体质,清除体内自由基,并具有活血行气、疏郁安神的功效。
4、本发明针对提取的玫瑰花-麦冬挥发油复合物的特定性质及兼顾其所含的多种挥发成分,确定了最佳的包合温度和包合配比,使药效更好更稳定。
5、本发明的组合物各原料来源丰富,无任何毒副作用,可以长期服用,通过各种原料的协同作用,改善产妇体质,功效持久,不易出现反弹。
具体实施方式
下面结合实施例对本发明技术方案作进一步说明。
实施例中可溶性淀粉
实施例1
本实施例祛斑组合物的原料及组成为:玫瑰花35份、银耳多糖35份、麦冬15份和叶酸0.01份。
本实施例祛斑组合物的制备方如下:
(1)将麦冬粉碎,过24目筛,与玫瑰花混合加5倍量水水蒸气蒸馏法提取挥发油,提取5h,收集挥发油,提取液过滤,得滤液1,滤渣加4倍量的体积比为30:50:20的水-乙醇-丙酮溶液,回流提取1h,过滤得滤液2,合并滤液1和滤液2,减压浓缩至60℃下相对密度1.10的浓缩液,再将浓缩液减压干燥至干膏粉中水分含量5.0%,粉碎,得干膏粉;
(2)将挥发油用β-环糊精包合,将β-环糊精与水以质量比1:12混合,水浴加热制成β-环糊精溶液,然后将挥发油以质量体积比为1:10g/ml溶于75%乙醇溶液制成挥发油溶液,按挥发油与β-环糊精质量比1:2.5进行包合,包合温度为55℃,搅拌30min,冰箱冷藏25h,抽滤得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和叶酸混合均匀,在60℃下干燥消毒3小时,经粉碎,过筛,得祛斑组合物。
实施例2
本实施例祛斑组合物的原料及组成为:玫瑰花20份、银耳多糖50份、麦冬10份和亚叶酸钙0.02份。
本实施例祛斑组合物的制备方如下:
(1)将麦冬粉碎,过65目筛,与玫瑰花混合加8倍量水蒸馏提取挥发油,提取7h,收集挥发油,提取液过滤,得滤液1,滤渣加6倍量的体积比为30:60:10的水-乙醇-丙酮溶液,回流提取3h,过滤得滤液2,合并滤液1和滤液2,减压浓缩至60℃下相对密度1.05的浓缩液,再将浓缩液减压干燥至干膏粉中水分含量6.0%,粉碎,得干膏粉;
(2)将挥发油用β-环糊精包合,将β-环糊精与水以质量比1:12混合,水浴加热制成β-环糊精水溶液,然后将挥发油以质量体积比为1:10g/ml溶于75%乙醇溶液,最后按挥发油与β-环糊精质量比1:4进行包合,包合温度为60℃,搅拌30min,冰箱冷藏20h,抽滤得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和亚叶酸钙混合均匀,在60℃下干燥消毒1小时,经粉碎,过筛,得祛斑组合物。
实施例3
本实施例祛斑组合物的原料及组成为:玫瑰花50份、银耳多糖20份、麦冬20份和叶酸0.01份。
本实施例祛斑组合物的制备方如下:
(1)将麦冬粉碎,过24目筛,与玫瑰花混合加6倍量水蒸馏提取挥发油,提取3h,收集挥发油,提取液过滤,得滤液1,滤渣加6倍量的体积比为30:55:15的水-乙醇-丙酮溶液,回流提取3h,过滤得滤液2,合并滤液1和滤液2,减压浓缩至60℃下相对密度1.05的浓缩液,再将浓缩液减压干燥至干膏粉中水分含量8.0%,粉碎,得干膏粉;
(2)将挥发油用环糊精包合,将β-环糊精与与水以质量比1:12混合,水浴加热制成β-环糊精水溶液,然后将挥发油以质量体积比为1:10g/ml溶于75%乙醇溶液,最后按挥发油与环糊精以质量比1:3进行包合,包合温度为40℃,搅拌30min,冰箱冷藏24h,抽滤得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和叶酸混合均匀,在70℃下干燥消毒3小时,经粉碎,过筛得祛斑组合物。
实施例1-1
本实施例与实施例1的区别是将麦冬15份去掉,将玫瑰花调整为50份,其余与实施例1保持一致。
实施例1-2
本实施例与实施例1的区别是将玫瑰花去掉,将麦冬的份数调整为50份,其余与实施例1保持一致。
实施例1-3
本实施例与实施例1的区别是将制备方法中步骤(1)中水提取溶剂体积比为30:50:20的水-乙醇-丙酮溶液调整为70%乙醇溶液,其余与实施例1保持一致。
实施例1-4
本实施例与实施例1的区别是,将步骤(2)中包合温度调整为30℃,其余与实施例1保持一致。
实施例1-5
本实施例与实施例1的区别是,组合物的原料为玫瑰花40份、银耳多糖15份、麦冬25份和叶酸0.5份。
实施例1-6
本实施例与实施例1的区别是,将步骤(2)中挥发油与β-环糊精的质量比为1:1,其余与实施例1保持一致。
试验例1
1.1目的:研究本发明药物对黄褐斑大鼠的治疗作用,对相关生化指标的影响;
1.2方法:腿部注射黄体酮复制黄褐斑大鼠模型,灌胃给药各实施例5周后,分别测定血清中超氧化物歧化酶、丙二醛的含量及皮肤超氧化物歧化酶、丙二醛、酪氨酸的含量;
1.3实验材料:黄体酮(1ml/20mg):浙江医药股份有限公司仙琚制药厂;SOD、MDA试剂盒:南京建成生物工程研究所;
1.4实验动物:SD大鼠,体重200±50g,普通级,雌性未孕,共55只;购自北京维通利华试验技术有限公司,许可证编号:生产许可SCXK(沪)2017-0011。于清洁环境中自由进食。
1.5实验步骤:
(1)黄褐斑大鼠模型的复制:将50只雌性大鼠,采用黄体酮肌注7.5mg/kg,注射时间为30d,复制黄褐斑大鼠模型。另取5只大鼠,注射等体积生理盐水。
(2)分组及给药:将上述50只大鼠按随机数字表分为模型组、实施例1组,实施例2组,实施例3组,实施例1-1组,实施例1-2组,实施例1-3组,实施例1-4组,实施例1-5组,实施例1-6组;每组5只。另外注射生理盐水的5只作为正常组。按0.3g/kg剂量每天灌胃给药1次,连续2周,每周检测一次体重。
(3)末次给药禁食12h,称重,切取大鼠皮肤1块、肝脏1块,各称取1.2g,加入10ml预冷生理盐水匀浆,3000r/min离心15min,制备血清,按照试剂盒操作检测血清中SOD、MDA含量,采用同步荧光分析法检测酪氨酸的含量,结果见表1。
表1各实施例组对模型大鼠SOD、MDA和酪氨酸的含量的影响
注:不同字母之间表示两组比较p<0.05,差异具有显著性。
试验例2急性毒性实验
2.1目的:评价本发明祛斑组合物的毒副作用
2.2实验材料:健康成年ICR系小鼠;灌胃针,动物体重秤,注射器,实施例1祛斑组合物;2.3分组及给药:健康成年雌性小鼠50只,体重20±2g,按照随机数字表分成5组,称取祛斑组合物10g、50g、100g、200g、300g分别溶于100ml纯化水中,制成浓度分别为0.1g/ml、0.5g/ml、1.0g/ml、2.0g/ml、3.0g/ml的祛斑组合物溶液。5组小鼠分别灌胃不同浓度的祛斑组合物溶液,小鼠灌胃体积为0.5ml/10g。给药4h后观察1次,之后每天早晚各观察1次,连续观察7d。观察目标主要有小鼠被毛的光滑度,小鼠的活动,眼角膜血丝情况,小鼠饮食,体重,并记录小鼠的死亡数,试验中若有小鼠中毒死亡则对其进行剖检,观察各组织器官的变化。
2.4实验结果
试验例3人体试食试验
本发明按照《保健食品检验与评价规范》对面部有黄褐斑及产后轻中度抑郁的人群进行人体试食试验。
受试者纳入标准为符合下列要求的自愿受试者:
1.面部淡褐色至深褐色斑点,界限清楚的斑片,无炎性表现;
2.病情有一定的季节性,夏重冬轻;
3.除内分泌以外无明显其他疾病引起的色素沉着。
试验样品:实施例1、实施例1-5制备的祛斑组合物颗粒剂,温水冲服;
试验设计及分组:选择自愿参加的脸部胳膊上有色斑、主诉产后焦虑、情绪不稳定、睡眠质量差的产妇(均已过哺乳期10个月)志愿者30名,年龄28-36岁。分组时尽可能考虑影响结果的主要因素如户外活动情况、性别、年龄等,进行均衡性检验,以保证组间的可比性。
试验方法:各组志愿者口服祛斑组合物颗粒剂,1g/次,一日三次,连续试吃2个月,试用期间不改变原来的饮食习惯。
观察指标:
安全性指标:
一般指标:精神、睡眠、饮食、大小便、血压等。
功效指标:
(1)颜面部黄褐斑面积大小检测用标尺测量受试前后整个颜面部黄褐斑的面积(mm2)
(2)颜面部黄褐斑颜色深浅检测按中国科学院地理研究所设计研制,测绘出版社1992年出版的《实用标准色卡》(第一版)中的棕色(Y+M+BK即黄+品红+黑的叠色)色卡为黄褐斑深浅的判断标准:Ⅰ度(15,20,5),Ⅱ度(30,40,10),Ⅲ度(40,60,15)。
数据处理和结果判定
对试食前后黄褐斑颜色积分和面积变化进行统计分析,同时计算有效率。色卡Ⅰ度、Ⅱ度、Ⅲ度分别记1分、2分和3分。
功效判定标准:
祛斑有效:黄褐斑颜色下降Ⅰ度,面积减少大于10%,且不产生新黄褐斑;
祛斑无效:黄褐斑颜色及面积无明显变化。
缓解焦虑有效:根据受试者主诉,焦虑、烦躁情绪明显缓解,心情放松;
缓解焦虑无效:根据受试者主诉,情绪无明显变化;
改善睡眠有效:根据受试者主诉,入睡容易,做梦减少,醒来疲乏感减少;
改善睡眠无效:根据受试者主诉,睡眠与往常无区别。
结果判定:试食组黄褐斑面积平均减少,且大于等于10%,颜色积分明显下降,自身前后比较及与对照组比较,差别均有显著性,且不产生新的黄褐斑,可判定该受试样品具有祛黄褐斑功能作用。
实验结果分析:采用t检验进行分析。自身对照资料采用配对t检验。
(1)安全性评价:试验前后两组产妇志愿者精神、饮食、大小便、血压等与试吃前无差异。
(2)各实验组志愿者黄褐斑面积减少情况
注:与自身对照相比,*P<0.01,#P<0.05。
(3)黄褐斑颜色变化比较(积分)
分组 | 人数 | 试吃前 | 试吃后 | 差值 |
实施例1组 | 15 | 2.0±0.7 | 0.9±0.4<sup>*</sup> | 1.1 |
实施例1-5组 | 15 | 1.9±0.1 | 1.4±0.2<sup>#</sup> | 0.5 |
注:与自身对照相比,*P<0.01,#P<0.05。
(4)祛黄褐斑、缓解情绪、安神功效
结果分析:本发明将已过哺乳期的产妇随机分组,并考虑影响结果的主要因素如户外活动情况、性别、年龄等,各组间具有可比性。由结果可知,本发明的祛斑组合物颗粒剂食用2个月后,对产妇具有较明显的祛斑、淡斑、缓解受试者焦虑情绪、改善睡眠的作用。
上述详细说明是针对本发明其中之一可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明所为的等效实施或变更,均应包含于本发明技术方案的范围内。
Claims (7)
1.一种适合产妇用的祛斑解郁组合物,其特征在于,所述组合物的原料由如下重量份数的组分组成:玫瑰花30-40份、银耳多糖30-40份、麦冬10-15份和叶酸类化合物0.01-0.02份;
所述的祛斑解郁组合物的制备方法,包括如下步骤:
(1)将麦冬粉碎,与玫瑰花混合加5-8倍量水经水蒸气蒸馏提取挥发油,提取5-7h,收集挥发油,提取液过滤,得滤液1,滤渣加4-6倍量的体积比为30:50-60:10-20的水-乙醇-丙酮溶液,回流提取1-3h,过滤得滤液2,合并滤液1和滤液2,浓缩,干燥,得干膏粉;
(2)将挥发油用β-环糊精包合,得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和叶酸类化合物混合均匀后,得祛斑组合物;
步骤(2)中所述的包合温度为40-60℃,所述挥发油与β-环糊精的质量比为1:2.5-4。
2.根据权利要求1所述的祛斑解郁组合物,其特征在于,所述组合物的原料由如下重量份数的组分组成:玫瑰花35份、银耳多糖35份、麦冬15份和叶酸类化合物0.015份。
3.根据权利要求1-2任意一项所述的祛斑解郁组合物,其特征在于,所述的叶酸类化合物为叶酸、甲酰四氢叶酸、L-甲基叶酸、叶酸可药用盐或叶酸可药用盐的活性代谢产物中的一种或几种。
4.一种根据权利要求1-3任意一项所述的祛斑解郁组合物的制备方法,其特征在于,包括如下步骤:
(1)将麦冬粉碎,与玫瑰花混合加5-8倍量水经水蒸气蒸馏提取挥发油,提取5-7h,收集挥发油,提取液过滤,得滤液1,滤渣加4-6倍量的体积比为30:50-60:10-20的水-乙醇-丙酮溶液,回流提取1-3h,过滤得滤液2,合并滤液1和滤液2,浓缩,干燥,得干膏粉;
(2)将挥发油用β-环糊精包合,得挥发油包合物;
(3)将干膏粉、挥发油包合物、银耳多糖和叶酸类化合物混合均匀后,得祛斑组合物。
5.根据权利要求4所述的祛斑解郁组合物的制备方法,其特征在于,步骤(1)中麦冬粉碎后过24-65目筛;所述浓缩为浓缩至60℃下相对密度为1.05±0.05;所述干燥均为减压真空干燥,干燥至干膏粉水分含量≤8%。
6.根据权利要求4所述的祛斑解郁组合物的制备方法,其特征在于,步骤(3)混合后还包括在60~70℃下干燥消毒1~3小时,经粉碎,过筛,即得。
7.一种根据权利要求1-3任意一项所述的祛斑解郁组合物或权利要求4-6任意一项所述的制备方法制备的祛斑解郁组合物在制备祛斑食品、保健品或药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110157222.4A CN112870290B (zh) | 2021-02-04 | 2021-02-04 | 一种祛斑解郁组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110157222.4A CN112870290B (zh) | 2021-02-04 | 2021-02-04 | 一种祛斑解郁组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112870290A CN112870290A (zh) | 2021-06-01 |
CN112870290B true CN112870290B (zh) | 2022-06-10 |
Family
ID=76057300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110157222.4A Active CN112870290B (zh) | 2021-02-04 | 2021-02-04 | 一种祛斑解郁组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112870290B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112869160B (zh) * | 2021-02-04 | 2022-11-18 | 建昌帮药业有限公司 | 一种含叶酸的祛斑组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104887826A (zh) * | 2015-05-07 | 2015-09-09 | 成都荣康科技有限责任公司 | 一种祛黄褐斑、缓解便秘、排毒养颜功能的中药组合物及其制备方法 |
CN108785459A (zh) * | 2018-08-14 | 2018-11-13 | 北京斯利安药业有限公司 | 一种适合孕妇用的祛斑组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101095751B (zh) * | 2006-12-15 | 2011-04-13 | 兰州奇正健康日用品有限公司 | 具有祛黄褐斑、改善营养性贫血的药物组合物及制备方法 |
CN103893533A (zh) * | 2013-10-28 | 2014-07-02 | 东南大学 | 一种用于美白的中药配方组成及其使用方法 |
CN107647042A (zh) * | 2017-08-22 | 2018-02-02 | 贵州芳瑞堂生物科技有限公司 | 一种美白祛斑茶 |
-
2021
- 2021-02-04 CN CN202110157222.4A patent/CN112870290B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104887826A (zh) * | 2015-05-07 | 2015-09-09 | 成都荣康科技有限责任公司 | 一种祛黄褐斑、缓解便秘、排毒养颜功能的中药组合物及其制备方法 |
CN108785459A (zh) * | 2018-08-14 | 2018-11-13 | 北京斯利安药业有限公司 | 一种适合孕妇用的祛斑组合物及其应用 |
CN109331094A (zh) * | 2018-08-14 | 2019-02-15 | 北京斯利安药业有限公司 | 一种适合孕妇用的祛斑组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112870290A (zh) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103007035B (zh) | 一种清肝明目的枸杞叶中药茶饮及其制备方法 | |
CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
CN103141709A (zh) | 一种鲤鱼饲料及其制备方法 | |
CN102048224B (zh) | 一种祛黄褐斑美容养颜红枣保健饮料及其生产工艺 | |
KR101855821B1 (ko) | 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물 | |
CN1408397A (zh) | 含褪黑素和益智中药的组合物 | |
CN112870290B (zh) | 一种祛斑解郁组合物及其制备方法 | |
CN107308323B (zh) | 补脑口服液及其制备工艺 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN104027428B (zh) | 一种中药复方的制备方法及在防治老年痴呆症中的应用 | |
CN107912773A (zh) | 一种用于缓解体力疲劳的制剂 | |
CN112869160B (zh) | 一种含叶酸的祛斑组合物及其制备方法 | |
CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
KR101160088B1 (ko) | 알코올성 지방간과 고지혈증 억제 및 숙취 억제 조성물 | |
CN105998191A (zh) | 全麻素在制备治疗痛风药物中的应用 | |
CN112843155B (zh) | 一种适合产妇用的祛斑及缓解腰痛的组合物 | |
CN106421741A (zh) | 水溶性橄榄叶提取物保健品及其制备方法 | |
CN114081171A (zh) | 一种具有辅助改善睡眠作用的功能性食品组合物 | |
CN110250514A (zh) | 祛黄褐斑的保健食品及其制备方法 | |
CN105925447B (zh) | 一种含有金花葵的复方保健酒及其制备方法和用途 | |
CN101537079B (zh) | 改善睡眠、延缓衰老的药物组合物或保健品及其制备方法 | |
CN109010788A (zh) | 改善睡眠及尿频尿急夜尿频多症的组合物与制备工艺 | |
NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
CN112641809B (zh) | 一种林蛙籽及其提取物在制备减肥药品和食品中的应用 | |
CN100393339C (zh) | 滋肾健脑药及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |